DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/j7kg94/how_will_new) has announced the addition of Decision Resources, Inc's new report "How Will New Entrants Alter the Biologics Landscape in Ankylosing Spondylitis and Psoriatic Arthritis? A European Physician and Payer Perspective" to their offering.
The approval of tumor necrosis factor-alpha (TNF-a) inhibitors filled a critical unmet need in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) given the limited efficacy of conventional disease-modifying antirheumatic drugs (DMARDs) in these diseases. Four TNF-a inhibitors are currently marketed for PsA and AS, with a fifth - UCB/Otsuka's Cimzia - in Phase III trials for PsA and axial spondyloarthritis (SpA; includes AS and undifferentiated axial SpA). The lack of targeted immune therapies other than TNF-a inhibitors approved in these indications signals clear opportunities for drug developers to bring agents to market that offer treatment alternatives.
Indeed, late-stage candidates with alternative mechanisms of action and varied dosage forms populate the pipelines for PsA and AS, setting the stage for treatment to evolve beyond TNF-a inhibition. Further driving interest in axial SpA, recent updates to international guidelines recommend use of TNF-a inhibitors in patients with undifferentiated axial SpA refractory to conventional agents, considered to be a possible precursor condition to AS.
Key Topics Covered:
- Executive Summary
- Commercial Context
- Methodology
- Overview and Analysis of Reimbursement in the EU5
- Analysis of Survey Results
- European Healthcare Briefing
- About the Author
- For Further Information
For more information visit http://www.researchandmarkets.com/research/j7kg94/how_will_new
Source: Decision Resources, Inc